Synchron Raises US$200 Million to Advance BCI Technology
Synchron has secured US$200 million in a Series D funding round aimed at accelerating the commercialization of its first-generation Stentrode brain-computer interface (BCI) and pushing forward the creation of a next-generation, transcatheter, high-channel whole-brain interface.
Goals and Development Plans
The company plans to use this capital to speed up pivotal trials, prepare for the market debut of the Stentrode BCI system, and expand its team of engineers, neuroscientists, and operators to enhance the future of neurotechnology.
Investment and Key Participants
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
“With this Series D funding, Synchron will continue hiring and expanding its engineering and neuroscience teams to advance the next generation of brain-computer interfaces.”
Total Funding Achieved
According to Synchron’s announcement, this round brings its total funding to US$345 million.
Author’s summary: The new US$200 million boost positions Synchron to accelerate BCI commercialization and strengthen development of its next-gen neural interface platform.